ES2584541T3 - Receptor de linfocitos T - Google Patents

Receptor de linfocitos T Download PDF

Info

Publication number
ES2584541T3
ES2584541T3 ES10777061.2T ES10777061T ES2584541T3 ES 2584541 T3 ES2584541 T3 ES 2584541T3 ES 10777061 T ES10777061 T ES 10777061T ES 2584541 T3 ES2584541 T3 ES 2584541T3
Authority
ES
Spain
Prior art keywords
tcr
seq
chain
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10777061.2T
Other languages
English (en)
Spanish (es)
Inventor
Hans Stauss
Shao-An Xue
Max Topp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES2584541T3 publication Critical patent/ES2584541T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES10777061.2T 2009-09-29 2010-09-28 Receptor de linfocitos T Active ES2584541T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0917090 2009-09-29
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Publications (1)

Publication Number Publication Date
ES2584541T3 true ES2584541T3 (es) 2016-09-28

Family

ID=41350560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10777061.2T Active ES2584541T3 (es) 2009-09-29 2010-09-28 Receptor de linfocitos T

Country Status (10)

Country Link
US (1) US8889141B2 (https=)
EP (1) EP2483294B1 (https=)
JP (2) JP6180114B2 (https=)
KR (1) KR101760277B1 (https=)
CN (1) CN102695717B (https=)
AU (1) AU2010302477B2 (https=)
ES (1) ES2584541T3 (https=)
GB (1) GB0917090D0 (https=)
IN (1) IN2012DN02993A (https=)
WO (1) WO2011039508A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
CN107858333B (zh) 2011-10-28 2022-05-27 瑞泽恩制药公司 T细胞受体基因修饰小鼠
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
CA2884366A1 (en) * 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
ES2745472T3 (es) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
MX375379B (es) * 2014-05-29 2025-03-06 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
EP4248744A3 (en) 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
AU2016274767B2 (en) * 2015-06-09 2022-05-19 Eureka Therapeutics, Inc. T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
EP3350600A4 (en) 2015-09-18 2019-04-17 Baylor College of Medicine DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
WO2018050825A1 (de) * 2016-09-19 2018-03-22 Bayer Cropscience Aktiengesellschaft Pyrazolo[1,5-a]pyridin- derivative und ihre verwendung als schädlingsbekämpfungsmittel
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽
US11918634B2 (en) 2017-08-10 2024-03-05 Good T Cells, Inc. Method for activating T cells for cancer treatment
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US12139523B2 (en) 2018-11-27 2024-11-12 Duke University Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
CN113423724B (zh) * 2018-12-27 2023-11-24 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Also Published As

Publication number Publication date
JP6180114B2 (ja) 2017-08-16
CN102695717B (zh) 2016-08-10
JP2016047064A (ja) 2016-04-07
GB0917090D0 (en) 2009-11-11
US8889141B2 (en) 2014-11-18
EP2483294B1 (en) 2016-07-13
KR101760277B1 (ko) 2017-07-21
WO2011039508A3 (en) 2011-06-30
AU2010302477B2 (en) 2017-01-19
KR20120074291A (ko) 2012-07-05
CN102695717A (zh) 2012-09-26
EP2483294A2 (en) 2012-08-08
IN2012DN02993A (https=) 2015-07-31
JP2013505734A (ja) 2013-02-21
AU2010302477A1 (en) 2012-04-19
WO2011039508A2 (en) 2011-04-07
US20120244132A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
ES2584541T3 (es) Receptor de linfocitos T
EP2483303B1 (en) T-cell receptor capable of recognising an antigen from cytomegalovirus
ES3027565T3 (en) Tcr and peptides
US20250154532A1 (en) Engineered regulatory t cell
RU2665548C2 (ru) Способ получения клеток, экспрессирующих т-клеточный рецептор
US20220119477A1 (en) Tcr and peptides
CN117264043A (zh) 靶向kras g12v突变多肽的t细胞受体及其用途
JP2026041767A (ja) ループスを処置するための組成物及び方法
US10251936B2 (en) EBV antigen specific T-cell receptor and use thereof
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
CN119661688A (zh) 一种特异性t细胞抗原受体及其制备方法和其应用
CN117736298A (zh) T细胞抗原受体及其制备方法和应用